The biotech company Curevac plans to spend less money next year. Curevac expects a decline in cash spending in 2022 after the high research and development costs of this year for the first-generation corona vaccine candidate, which has now been withdrawn, said CFO Pierre Kemula in an interview with analysts on Friday. The current liquidity situation is “comfortable” at 1.06 billion euros (as of the end of September). The company is also considering issuing shares up to $ 600 million, subject to market conditions. Curevac had given up its first Covid vaccine candidate CVnCoV in October after disappointing study results in order to focus on the development of an improved mRNA vaccine with the British pharmaceutical company GSK. The first clinical trials are scheduled to begin in the next few months – in the fourth quarter of 2021. In the first nine months of 2021, Curevac increased sales by 44 percent to 61.8 million euros. The pre-tax loss jumped to 407.9 million euros after a deficit of 72.6 million.
Biotechnology – Curevac wants to spend less money – economy
